Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Pre-diagnostic route reported by patients with sarcoma from the Netherlands, the UK, Australia and New Zealand: early detection challenges for general practitioners - an international observational cohort study.

BMJ open·2026
Same author

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Nature communications·2026
Same author

Overcoming Diagnostic and Therapeutic Challenges in Primary Cardiac Angiosarcoma.

JACC. Case reports·2026
Same author

Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium.

European journal of cancer (Oxford, England : 1990)·2026

相关实验视频

Updated: Jun 3, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K

在软组织肉 Sarcoma 的新疗法.

Leonidas Mavroeidis1, Andrea Napolitano1, Paul Huang1

  • 1Sarcoma Unit, The Royal Marsden Hospital and Institute of Cancer Research, London SW3 6JZ, UK.

Cancers
|January 11, 2025
PubMed
概括

软组织肉瘤 (STS) 治疗的最新进展包括FDA批准的向疗法和免疫疗法. 克服罕见和异质性STS的挑战需要更好的生物学理解和新的药物开发战略.

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 软组织肉瘤 (STS) 是一种罕见且异质的癌症群.
  • 在了解STS分子特征和开发向治疗方面取得了重大进展.

研究的目的:

  • 审查最近在软组织肉瘤的分子表征和治疗方法方面的进展.
  • 要突出FDA批准的新型药物和各种STS亚型的试验性治疗方法.

主要方法:

  • 审查最近FDA批准的新药在STS治疗中的新药.
  • 针对STS.中的特定分子变化和途径的试验性疗法的摘要.
  • 讨论在STS药物开发中的挑战和未来方向.

主要成果:

  • 一些新型药物,包括氨酸激酶抑制剂 (avapritinib,ripretinib),免疫检查点抑制剂 (atezolizumab) 和其他药物 (nirogacestat,larotrectinib,entrectinib,nab-sirolimus,tazemetostat),已获得FDA对特定STS亚型的批准.
  • 诸如MDM2和CDK4/6抑制剂,其他免疫检查点抑制剂和PARP抑制剂等研究中的治疗方法显示出有前途.
  • 在突肉瘤中进行自主T细胞治疗 (afami-cel) 获得了加速批准.
关键词:
药物开发是药物的发展.软组织肉瘤软组织肉瘤治疗药物 治疗药物治疗治疗治疗治疗治疗治疗

更多相关视频

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.2K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.8K

相关实验视频

Last Updated: Jun 3, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.2K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.8K

结论:

  • 尽管稀有性和分子异质性带来了挑战,但在软组织肉瘤中取得了显著的治疗进展.
  • 未来的进展取决于对STS生物学有更深入的理解,开发用于具有挑战性的目标的新型化合物 (例如,蛋白质溶解向金马 - PROTACs),创新的临床试验设计,以及行业和学术界的合作.